Quantcast
Channel: Endpoints News
↧

Crystalys lands $205M to bring gout drug first marketed in Japan to the US...

A team that got a gout treatment approved is coming back together to develop a new medicine for the condition in the US and Europe. Crystalys Therapeutics, the San Diego biotech developing the oral...

View Article


White House confirms Section 232 pharma investigation has resulted in 100%...

A White House official confirmed to Endpoints News that President Donald Trump’s social media post which said he'd put 100% tariffs on some branded drugs is a result of the administration's five-month...

View Article


Walmart takes on wellness

Last Thursday, I stopped by Walmart’s first ever wellness event in swanky Chelsea, Manhattan. Influencers and members of the press milled about, sipping on healthy smoothies, playing pickleball,...

View Article

MFN updates: Trump drug price announcement on most favored nation

President Donald Trump said Tuesday that Pfizer has agreed to offer all new medicines at “most favored nation” prices, the first drugmaker to make a deal in line with the White House’s push to tie ...

View Article

Barinthus’ reverse merger with private biotech; Sutro to lay off 33% of...

Plus, news about Ocular Therapeutix, Kardigan, ARS Pharmaceuticals, Full-Life Technologies, Orion, Novo Nordisk, Nxera Pharma and UniQure: 📈 Barinthus Biotherapeutics inks reverse merger: The UK...

View Article


Merck makes the case for PAH drug Winrevair in patients with earlier disease

Merck's pulmonary arterial hypertension drug Winrevair cut the risk of “clinical worsening” — an endpoint made up of a variety of signs showing that a patient's illness is progressing — by 76% in...

View Article

Under new CEO, Novo ends heart failure partnership with Japanese biotech

A small Japanese biotech said it was blindsided by Novo Nordisk’s decision to terminate their work developing a stem cell-based therapy for heart failure. The Danish drug giant ended the collaboration,...

View Article

‘Likely’ government shutdown threatens to stress an already depleted FDA

Absent an agreement before midnight, the federal government is headed for a shutdown on Wednesday, potentially leading to tens of thousands of furloughs at HHS and further complicating the work of a...

View Article


FDA approves Novartis' BTK inhibitor for chronic hives

The FDA on Tuesday approved Novartis' BTK inhibitor to treat patients with chronic spontaneous urticaria, also known as chronic hives. The drug, remibrutinib, will be branded as Rhapsido. It’s the...

View Article


What we do and don’t know after the White House’s deal with Pfizer

The White House heralded its new drug pricing agreement with Pfizer, saying it was prioritizing fairness for American consumers and that it would be the first of many deals struck with drug...

View Article

After building Ochre Bio, Jack O'Meara's newest biotech raises $21M for neuro...

A biotech in Dublin and London wants to jump into the bustling RNAi and brain shuttle fields to create precision medicines for neurodegenerative diseases. The biotech, named Aerska, launched Wednesday...

View Article

Vertanical unpacks Phase 3 success for cannabis-based painkiller

Vertanical has shared positive results from its only asset in a late-stage trial of 820 people with chronic lower back pain as it awaits the outcome of a review in certain European countries. On...

View Article

Ansa Biotechnologies closes $54.4M Series B to boost US DNA manufacturing 

California-based synthetic DNA maker Ansa Biotechnologies has closed an oversubscribed Series B funding round with $45.2 million, plus commitments for an additional $9.2 million. The cash will be used...

View Article


FDA rejects treatment for rare copper deficiency over manufacturing

The FDA has rejected a copper replacement therapy for a rare and fatal genetic condition called Menkes disease, Fortress Biotech and its subsidiary Cyprium Therapeutics announced Wednesday morning....

View Article

Post-Hoc Live: Unpacking Trump and Pfizer’s 'most favored nation' deal

After months of negotiations and anticipation, the Trump administration finally rolled out the first of its deals with drugmakers under its “most favored nation” policy. We’ve been tracking talks...

View Article


Enanta aims to raise $50M as it advances RSV therapy; Hinge, Kyorin make a deal

Plus, news about Palisade Bio, Betta Pharmaceuticals, Binhui Biopharmaceutical, Appili Therapeutics, Vitalex Biosciences, Alpha Cognition, Klotho Neurosciences and Turn Biotechnologies: 💰 Enanta seeks...

View Article

Halozyme to spend $750M upfront to buy Elektrofi, a biologics tech delivery...

Halozyme Therapeutics is buying a peer in drug delivery technology with a $750 million deal for privately-held Elektrofi, the companies said Wednesday morning. Halozyme has built up a broad suite of ...

View Article


Takeda stops all work in cell therapy 

Takeda is discontinuing its cell therapy efforts after it already pared back its work in the field. It’s another blow to a cell therapy industry that has fallen out of favor as companies struggled to ...

View Article

Exclusive: French startup's gene therapy dramatically reduces urinary...

A Paris-based biotech startup unveiled the first results for its gene therapy designed to reduce uncontrolled urination in people with spinal cord injury. In an exclusive interview with Endpoints News,...

View Article

Trump’s 100% pharma tariff won’t start Oct. 1, White House confirms

The Trump administration is starting to prepare tariffs on some pharma companies, but those levies won’t take effect on Wednesday, a White House official confirmed to Endpoints News. President Donald...

View Article

Biogen owes Genentech $88M in royalties from Tysabri, court rules

Biogen should pay Genentech more than $88 million in additional royalties for using Genentech’s patented process to help make the monoclonal antibody Tysabri, a California federal judge ruled. The case...

View Article


Pfizer-White House deal prompts pharma rally on Wall Street

Of all the obstacles that the pharmaceutical industry has faced in the first year of President Donald Trump’s second term, none have struck more fear in executives, board rooms and investors than the...

View Article


Third-round IRA guidance spells out new orphan drug protections

CMS finalized guidance this week that the agency says will increase transparency in the third round of Medicare drug price negotiations and “preserve critical incentives for rare disease research.” The...

View Article

Exclusive: Upcoming ACIP meeting may move to December

The CDC is considering rescheduling the next meeting of the Advisory Committee on Immunization Practices for December, an administration official told Endpoints News. The official, granted anonymity to...

View Article